- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
CAR-T cell therapy in Multiple Myeloma: current status and future challenges ; volume:14 ; number:1 ; day:26 ; month:11 ; year:2024 ; pages:1-16 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (26.11.2024), 1-16, 12.2024
- Creator
-
Swan, Dawn
Madduri, Deepu
Hocking, Jay
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-01191-8
- URN
-
urn:nbn:de:101:1-2502112119041.038768777215
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Swan, Dawn
- Madduri, Deepu
- Hocking, Jay
- SpringerLink (Online service)
Other Objects (12)
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Establishing guidelines for CAR-T cells: challenges and considerations
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Establishing guidelines for CAR-T cells: challenges and considerations
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
CAR-T cells in multiple myeloma: current status
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth
Non‐BCMA targeted CAR‐T cell therapies for multiple myeloma
Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Establishing guidelines for CAR-T cells: challenges and considerations
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Engineering CAR-T cells
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients